+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Humatrope"

Somatotropin deficiency - Pipeline Insight, 2024 - Product Thumbnail Image

Somatotropin deficiency - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 80 Pages
  • Global
From
From
Humatrope - API Insight, 2022 - Product Thumbnail Image

Humatrope - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Humatrope- Drug Insight, 2019 - Product Thumbnail Image

Humatrope- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Humatrope is a brand of recombinant human growth hormone (rHGH) used to treat endocrine and metabolic disorders. It is used to treat growth failure in children and adults due to inadequate secretion of endogenous growth hormone, and to treat short stature associated with Turner Syndrome, Prader-Willi Syndrome, and chronic renal insufficiency. It is also used to treat adults with growth hormone deficiency. Humatrope is a biopharmaceutical product that is administered via subcutaneous injection. It is available in a variety of dosage strengths and is approved for use in the United States, Europe, and other countries. The Humatrope market is a competitive one, with several companies offering their own versions of the product. Companies in the market include Eli Lilly, Novo Nordisk, Pfizer, and Sandoz. Show Less Read more